^
Association details:
| Biomarker: | CYP17A1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer
Excerpt:
Pretreatment tumor nuclear AR overexpression (>75%) and CYP17 (>10%) expression were associated with benefit (p = 0.018).
DOI:
10.1016/j.eururo.2014.05.005
Trial ID:
